AcuCort

AcuCort Forward P/E

The Forward P/E Ratio of AcuCort (ACUC.SL) as of Oct 17, 2026 is -11.57. In the previous year, Forward P/E Ratio was -14.70 — a change of -21.31% (higher).

Forward P/E

-11.57

YoY

-21.31%

Last updated:

Forward P/E Ratio of AcuCort is 2024 -11.57 . Forward P/E Ratio of AcuCort was 2023 -14.70 . It decreases by -21.31% higher compared to the previous year.

The AcuCort Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2017
-43.17 SEK
Jan 1, 2018
-32.35 SEK
Jan 1, 2019
-24.04 SEK
Jan 1, 2020
-25.91 SEK
Jan 1, 2021
-17.77 SEK
Jan 1, 2022
-13.61 SEK
Jan 1, 2023
-14.70 SEK
Jan 1, 2024
-11.57 SEK
The AcuCort Forward P/E history
YEARForward P/EYoY
-11.57-21.31%
-14.70+8.02%
-13.61-23.45%
-17.77-31.41%
-25.91+7.78%
-24.04-25.69%
-32.35-25.06%
-43.17-58.25%
-103.40+11.97%
-92.35—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcuCort Stock analysis

What does AcuCort do? AcuCort AB is a pharmaceutical company based in Lund, Sweden, operating within the Health Care sector. The company focuses on the development, marketing, and sale of oral dissolvable films, specifically targeting medical applications. Its primary product, ISICORT, utilizes dexamethasone, a glucocorticoid, for treating acute allergic reactions and managing nausea and vomiting associated with chemotherapy. AcuCort AB has a small operational footprint, employing four full-time staff members. The company completed its initial public offering (IPO) on April 24, 2017, and is listed under the ticker ACUC.SL with ISIN SE0009695927. It maintains a website at https://acucort.se/ for further information. AcuCort AB operates predominantly in the Nordic region, with its headquarters situated in Lund, Skåne. The company's business model centers on the production and distribution of specialized pharmaceutical products designed to address specific medical needs. While details about its financial performance, market share, or additional product lines are not provided, the company's focus remains on its core product and regional market presence. Its operational scale reflects a startup or early-stage pharmaceutical enterprise with limited resources. The company's website serves as the primary source for updates and corporate information. AcuCort AB's activities are confined to the development and commercialization of oral film technology, emphasizing targeted therapeutic applications in healthcare. AcuCort is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcuCort stock

Forward P/E Ratio of AcuCort is -11.57 in 2024.

Forward P/E Ratio of AcuCort changed from -14.70 to -11.57, representing a -21.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio AcuCort since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's AcuCort with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — AcuCort

All Key Metrics — AcuCort